TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness

被引:76
作者
Rossi, Stefania [1 ]
Cordella, Martina [1 ]
Tabolacci, Claudio [1 ]
Nassa, Giovanni [2 ]
D'Arcangelo, Daniela [3 ]
Senatore, Cinzia [1 ]
Pagnotto, Paolo [1 ]
Magliozzi, Roberta [4 ]
Salvati, Annamaria [2 ]
Weisz, Alessandro [2 ,5 ]
Facchiano, Antonio [3 ]
Facchiano, Francesco [1 ]
机构
[1] ISS, Dept Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy
[2] Univ Salerno, Dept Med Surg & Dent, Lab Mol Med & Genom, Scuola Med Salernitana, Baronissi, SA, Italy
[3] IDI IRCCS, Lab Mol Oncol, Ist Dermopat Immacolata, Rome, Italy
[4] Univ Verona, Dept Neurol & Movement Sci, Neurol B, Verona, Italy
[5] Genomix4Life Srl, Baronissi, SA, Italy
关键词
Cancer; Cytokines; Inflammation; Malignancy; Metalloproteases; Cutaneous melanoma; Uveal melanoma; Proteomics; TNF; TUMOR-NECROSIS-FACTOR; GROWTH; INHIBITION; MIGRATION; INVASION; MMP-9; BRAF; PROGRESSION; EXPRESSION; PROLIFERATION;
D O I
10.1186/s13046-018-0982-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMelanoma aggressiveness determines its growth and metastatic potential. This study aimed at identifying new molecular pathways controlling melanoma cell malignancy.MethodsTen metastatic melanoma cell lines were characterized by their proliferation, migration and invasion capabilities. The most representative cells were also characterized by spheroid formation assay, gene- and protein- expression profiling as well as cytokines secretion and the most relevant pathways identified through bioinformatic analysis were tested by in silico transcriptomic validation on datasets generated from biopsies specimens of melanoma patients. Further, matrix metalloproteases (MMPs) activity was tested by zymography assays and TNF-alpha role was validated by anti-TNF cell-treatment.ResultsAn aggressiveness score (here named Melanoma AGgressiveness Score: MAGS) was calculated by measuring proliferation, migration, invasion and cell-doubling time in10human melanoma cell lines which were clustered in two distinct groups, according to the corresponding MAGS. SK-MEL-28 and A375 cell lines were selected as representative models for the less and the most aggressive phenotype, respectively. Gene-expression and protein expression data were collected for SK-MEL-28 and A375 cells by Illumina-, multiplex x-MAP-and mass-spectrometry technology. The collected data were subjected to an integrated Ingenuity Pathway Analysis, which highlighted that cytokine/chemokine secretion, as well as Cell-To-Cell Signaling and Interaction functions as well as matrix metalloproteases activity were significantly different in these two cell types. The key role of these pathways was then confirmed by functional validation. TNF role was confirmed by exposing cells to the anti-TNF Infliximab antibody. Upon such treatment melanoma cells aggressiveness was strongly reduced. Metalloproteases activity was assayed, and their role was confirmed by comparing transcriptomic data from cutaneous melanoma patients (n=45) and benign nevi (n=18).ConclusionsInflammatory signals such as TNF and MMP-2 activity are key intrinsic players to determine melanoma cells aggressiveness suggesting new venue sin the identification of novel molecular targets with potential therapeutic relevance.
引用
收藏
页数:17
相关论文
共 60 条
[1]   Intracellular targets of RGDS peptide in melanoma cells [J].
Aguzzi, Maria Simona ;
Fortugno, Paola ;
Giampietri, Claudia ;
Ragone, Gianluca ;
Capogrossi, Maurizio C. ;
Facchiano, Antonio .
MOLECULAR CANCER, 2010, 9
[2]   The biology of uveal melanoma [J].
Amaro, Adriana ;
Gangemi, Rosaria ;
Piaggio, Francesca ;
Angelini, Giovanna ;
Barisione, Gaia ;
Ferrini, Silvano ;
Pfeffer, Ulrich .
CANCER AND METASTASIS REVIEWS, 2017, 36 (01) :109-140
[3]   Management of Inflammatory Bowel Disease Patients with a Cancer History [J].
Beaugerie, Laurent .
CURRENT DRUG TARGETS, 2014, 15 (11) :1042-1048
[4]   Inhibition of cell proliferation, migration and invasion of B16-F10 melanoma cells by α-mangostin [J].
Beninati, Simone ;
Oliverio, Serafina ;
Cordella, Martina ;
Rossi, Stefania ;
Senatore, Cinzia ;
Liguori, Immacolata ;
Lentini, Alessandro ;
Piredda, Lucia ;
Tabolacci, Claudio .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 450 (04) :1512-1517
[5]   BRAFV600E: Implications for Carcinogenesis and Molecular Therapy [J].
Cantwell-Dorris, Emma R. ;
O'Leary, John J. ;
Sheils, Orla M. .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (03) :385-394
[6]   Molecular Mechanisms of Selective Estrogen Receptor Modulator Activity in Human Breast Cancer Cells: Identification of Novel Nuclear Cofactors of Antiestrogen-ERα Complexes by Interaction Proteomics [J].
Cirillo, Francesca ;
Nassa, Giovanni ;
Taralla, Roberta ;
Stellato, Claudia ;
De Filippo, Maria Rosaria ;
Arribrosino, Concetta ;
Baumann, Marc ;
Nyman, Tuula A. ;
Weisz, Alessandro .
JOURNAL OF PROTEOME RESEARCH, 2013, 12 (01) :421-431
[7]   Transglutaminase type 2 affects cell migration through post-translational modification of platelet-derived growth factor-BB [J].
Cordella, Martina ;
Tabolacci, Claudio ;
Rossi, Stefania ;
Senatore, Cinzia ;
Facchiano, Angelo M. ;
D'Arcangelo, Daniela ;
Facchiano, Antonio ;
Facchiano, Francesco .
AMINO ACIDS, 2017, 49 (03) :473-481
[8]   Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion [J].
Delaunay, Tiphaine ;
Deschamps, Lydia ;
Haddada, Meriem ;
Walker, Francine ;
Soosaipillai, Antoninus ;
Soualmia, Feryel ;
El Amri, Chahrazade ;
Diamandis, Eleftherios P. ;
Brattsand, Maria ;
Magdolen, Viktor ;
Darmoul, Dalila .
MOLECULAR ONCOLOGY, 2017, 11 (10) :1330-1347
[9]   The controversial role of TNF in melanoma [J].
Donia, Marco ;
Kjeldsen, Julie Westerlin ;
Svane, Inge Marie .
ONCOIMMUNOLOGY, 2016, 5 (04)
[10]   INTRAOCULAR ACTIVATION OF ANGIOGENIC AND INFLAMMATORY PATHWAYS IN UVEAL MELANOMA [J].
Dunavoelgyi, Roman ;
Funk, Marion ;
Sacu, Stefan ;
Georgopoulos, Michael ;
Zlabinger, Gerhard ;
Zehetmayer, Martin ;
Schmidt-Erfurth, Ursula .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (07) :1373-1384